Bladder Cancer Clinical Trial Monitor — NMIBC, MIBC & Urothelial Carcinoma

The urothelial cancer trial landscape in 2026

Bladder and urothelial cancer has seen dramatic treatment advances over the past five years. Enfortumab vedotin + pembrolizumab has displaced platinum-based chemotherapy as the preferred first-line treatment for metastatic urothelial carcinoma based on EV-302/KEYNOTE-A39 data. This paradigm shift has fundamentally changed what second-line and adjuvant trials need to deliver.

Simultaneously, the non-muscle-invasive bladder cancer (NMIBC) space has been reinvigorated by intravesical immunotherapy and targeted therapy programs addressing BCG-unresponsive disease — a setting with urgent unmet need and a growing number of approved and investigational options.

Metastatic urothelial carcinoma: the post-EV/pembro era

With enfortumab vedotin + pembrolizumab as the new standard, the landscape has shifted:

Second-line after EV + pembrolizumab

The key clinical question now: what do patients receive after progressing on EV + pembrolizumab? Active trials include:

• Platinum-based chemotherapy in the second-line position (now moved post-EV/pembro)
• FGFR3-targeted therapy (erdafitinib) in FGFR3-altered disease after EV/pembro
• Novel ADCs with different payloads or targets (TROP2, HER2, Nectin-4 with different linkers)
• LAG-3 and TIGIT combinations for immunotherapy-refractory disease

FGFR3 inhibitors: expanding the population

Erdafitinib is approved for FGFR3-altered urothelial carcinoma. The expansion program includes:

• FGFR3 inhibitors in earlier-line positions (first-line in FGFR3-altered patients)
• Next-generation selective FGFR3 inhibitors with improved tolerability (ocular toxicity reduction)
• FGFR3 ADCs: linking FGFR3-targeted antibody to cytotoxic payload
• FGFR3 inhibitor + immunotherapy combinations in FGFR3-altered subpopulation

Non-muscle-invasive bladder cancer (NMIBC): BCG-unresponsive disease

BCG-unresponsive NMIBC — disease that progresses despite BCG therapy — has become one of the most active areas of bladder cancer drug development. Multiple intravesical and systemic therapies are now in trials:

Intravesical immunotherapy and targeted therapy

• Intravesical nadofaragene firadenovec (approved): long-term outcomes and combination studies
• Intravesical IL-15 superagonist: N-803 (nogapendekin alfa inbakicept) — approved in combination with BCG
• CG0070 (oncolytic adenovirus): Phase 3 enrollment ongoing
• Intravesical gemcitabine + docetaxel: standard treatment at many centers, formalization in trials
• TAR-200 (sustained-release intravesical gemcitabine): Phase 3 data emerging

High-risk NMIBC: preventing progression to MIBC

For high-grade T1 and CIS disease at risk of muscle invasion:

• Systemic checkpoint inhibitors for high-risk NMIBC (pembrolizumab in BCG-naive and BCG-relapsing disease)
• Perioperative immunotherapy in radical cystectomy candidates who decline surgery
• Bladder-sparing protocols: chemoradiotherapy optimization

Muscle-invasive bladder cancer (MIBC): perioperative strategies

MIBC management centers on optimal perioperative therapy around radical cystectomy:

• Neoadjuvant EV + pembrolizumab: Phase 3 data emerging, potential to eliminate chemotherapy
• Adjuvant nivolumab: CheckMate 274 — 5-year data being updated
• ctDNA-guided adjuvant therapy: molecular detection of residual disease to select patients
• Bladder preservation: combined modality therapy (TMT) vs. cystectomy in MIBC

Who monitors bladder cancer clinical trials?

• Urothelial oncology pharma teams at companies with NMIBC, MIBC, or metastatic urothelial programs
• Clinical development groups designing post-EV/pembro second-line or perioperative MIBC trials
• Urologic oncology medical affairs teams tracking enrollment status and new trial openings
• Healthcare investors covering urothelial cancer-focused biotech companies
• Academic urologic oncologists reviewing what trials are available for referral

Related GU oncology and urothelial cancer trial monitors

• Prostate cancer clinical trials — shared urologic oncology infrastructure and overlapping immunotherapy programs
• Kidney cancer clinical trials — related GU oncology and overlapping IO/TKI programs
• Melanoma clinical trials — overlapping enfortumab vedotin and checkpoint inhibitor programs